News

Exploring Veterinary Collaboration Opportunities at BioFIT 2025

Exploring Veterinary Collaboration Opportunities at BioFIT 2025

Can-Fite's Expanding Veterinary Pipeline at BioFIT 2025

As veterinary oncology continues to evolve, the potential of Namodenoson, a promising Phase III cancer drug, emerges as a topic of interest. The veterinary market size is projected to reach a substantial $3.1 billion by 2030, indicating a growing need for innovative treatment options in this field.

BioFIT 2025: A Platform for Veterinary Innovation

Can-Fite BioPharma Ltd. will showcase its veterinary initiatives at the upcoming BioFIT 2025 conference in Strasbourg, France. This event is a significant European gathering that showcases advances in life sciences, focusing on fostering partnerships and investment opportunities in biotechnology.

Success Stories Fueling New Opportunities

Reflecting on previous experiences, Can-Fite's participation at BioFIT has proven fruitful. The collaboration with Vetbiolix for Piclidenoson, developed to treat osteoarthritis in dogs and cats, exemplifies how these events can lead to valuable partnerships. This collaboration is projected to generate an estimated $325 million in royalty revenues for the company.

Namodenoson: A Promising Candidate for Veterinary Oncology

At BioFIT 2025, Can-Fite will aim to establish a second veterinary partnership focusing on Namodenoson. The drug has shown notable anti-tumor effectiveness and has a strong safety profile, making it an ideal candidate for treating various cancers in animals.

Engaging with Industry Leaders

During the event, Can-Fite plans to engage in discussions with major players in the animal health sector, including Elanco Animal Health and Zoetis. These meetings serve as a crucial platform to explore collaborative efforts aimed at advancing Namodenoson's veterinary development.

The Road Ahead for Can-Fite BioPharma Ltd.

Can-Fite BioPharma (NYSE: CANF, TASE: CANF.TA) is at the forefront of drug development targeting cancer and inflammatory diseases. The company’s innovative pipeline includes Namodenoson, currently in several clinical trials. This proactive approach positions Can-Fite to capitalize on lucrative markets in the healthcare space.

Innovative Molecules at the Heart of Development

Beyond Namodenoson, Can-Fite has seen success with Piclidenoson for psoriasis and is evaluating its other candidates such as CF602, which has shown effectiveness in treating erectile dysfunction. Each of these potential treatments highlights the company’s commitment to improving health outcomes.

Maintaining Safety Standards

With over 1,600 patients participating in clinical studies, Can-Fite prioritizes safety, ensuring that their treatments are both effective and well-tolerated. This commitment enhances their credibility in the biotech market.

Conclusion

As Can-Fite prepares for BioFIT 2025, it embodies the spirit of innovation and partnership in veterinary medicine. By pursuing new collaboration opportunities for Namodenoson, the company is set to make a significant impact in veterinary oncology, ultimately enhancing the quality of care available for our beloved pets.

Frequently Asked Questions

What is Namodenoson?

Namodenoson is a Phase III anti-cancer drug candidate being developed for both human and veterinary oncology, demonstrating efficacy against various tumors.

What is the focus of Can-Fite at BioFIT 2025?

Can-Fite aims to establish partnerships focused on the veterinary applications of Namodenoson and build upon previous successful collaborations.

Which companies will Can-Fite engage with during the conference?

Can-Fite plans to hold discussions with major animal health companies such as Elanco Animal Health and Zoetis during BioFIT 2025.

How does Can-Fite ensure the safety of its drug candidates?

Can-Fite has an excellent safety profile based on extensive clinical studies involving over 1,600 patients, ensuring their treatments are safe for ongoing development.

What is the projected growth of the veterinary oncology market?

The veterinary oncology market is projected to reach $3.1 billion by 2030, reflecting a significant opportunity for innovative treatments like Namodenoson.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

Surfing Dogs Ride Waves, Support Orphan Pets

Updated Category News Views 3

Waves, Paws, and Passion Who would've thought that dogs catching waves could also catch hearts and wallets? Well, that's exactly what's happening today at Del Mar Dog Beach with the 21st Annual Surf Dog Surf-A-Thon revving up the excitement. It's a sun-soaked day in Rancho Santa Fe, California, right in the thick of things at the longest-running dog surf competition. For...

Continue Reading
First-Time Homeowners: Unseen Pitfalls of Insurance

Updated Category News Views 6

Understanding Homeowners Insurance: Beyond the Basics Most folks diving into homeownership for the first time get caught up in the whirlwind of price tags, loans, and knick-knacks for their new place. Meanwhile, the nitty-gritty of homeowners insurance often gets tossed to the side. But take it from a weary watchdog of financial storms—it’s those details in the policy...

Continue Reading
Regeneron Faces Legal Heat: Lead Plaintiff Deadline Looms

Updated Category News Views 6

Regeneron’s Tight Spot: Legal Showdown Well, here we go again—Regeneron Pharmaceuticals (NASDAQ:REGN) is under some serious heat. If you're an investor who faced significant losses with this biotech juggernaut, remember that the clock’s ticking down to the wire. By tomorrow, September 14, 2026, you need to decide if you're going to throw your hat in the ring for...

Continue Reading
Trial Disappointment: No Significant Gains in NSCLC

Updated Category News Views 21

Dissecting the Nuances of the EVOKE-03/KEYNOTE-D46 Trial Every once in a while, we come across a trial that rattles cages in the research community. Today, it's the EVOKE-03/KEYNOTE-D46 trial, a collision of hope and hard-knock reality. This Phase 3 trial, which sought to explore the potential combo of sacituzumab govitecan (SG) and pembrolizumab on metastatic non-small...

Continue Reading
PwC US and India Unite for Global Consultancy Powerhouse

Updated Category News Views 7

Rearranging the Consultancy Chessboard Piling onto the game of consultancy realignments, PwC just made a move reminiscent of playing strategy poker. They're tossing together PwC US and PwC India's advisory capabilities for a new joint venture. It’s like pushing two puzzle pieces to make a single colorful picture that stretches from the U.S. all the way to the...

Continue Reading
Ris-Rez May Set New Standard in Relapsed SCLC

Updated Category News Views 7

The Game-Changing Results Innovation in pharmaceuticals sometimes feels like a waiting game, but when a fresh breakthrough like this rolls in, it lights up the whole landscape. Risvutatug rezetecan, or Ris-Rez for short, has shown promising potential in the fight against relapsed small-cell lung cancer (SCLC) that has progressed after platinum-based therapy. Survival...

Continue Reading
MRI Surveillance Gains Ground in Lung Cancer Care

Updated Category News Views 7

Shifting the Standard: MRI's Rise in SCLC Treatment Here's a twist that baffles the traditionalists—ditch the prophylactic cranial irradiation (PCI) and catch clearer days with MRI surveillance for small-cell lung cancer (SCLC). The latest international phase III MAVERICK trial might just redraw the lines on what's considered standard care in this relentless disease....

Continue Reading
PANDAG G1 Debuts: Revolutionizing Lawn Care Efficiency

Updated Category News Views 6

The Future of Landscaping Unveiled Get this—PANDAG is set to shake things up at GaLaBau 2026 with their futuristic G1 autonomous mower. This isn't just another piece of lawn equipment; it's practically a tech marvel on wheels, weaving together LiDAR, AI Vision, RTK, and 4G tech to make it the ultimate multitasker for the landscaping industry. We're talking obstacle...

Continue Reading
GORGIE Unleashes Berry Burst: Target's New Drink Star

Updated Category News Views 6

GORGIE Targets Taste Buds with Berry Burst Ever feel like you're missing out on that energy drink everyone seems to be raving about? Well, GORGIE's out there making some noise again, and this time it's got a new punchy player in the game: Berry Burst. It's not just another drink; it's shaking things up in the energy aisle with its exclusive launch at Target. Modern style...

Continue Reading
UWM Faces Class Action Deadline: Key Insights for Investors

Updated Category News Views 3

The High Stakes Reality for UWM Investors If there's one thing that's certain in this jittery world of investing, it's that losses have a way of waking you up. Right now, anyone tied up with UWM Holdings Corporation (NYSE: UWMC) shares needs to keep their wits about them; we're barreling toward an October 13, 2026 deadline for a class action lawsuit. The clock's ticking...

Continue Reading

Top 5 Most Recently Viewed Articles

Key Financial Trends Shaping Markets for Investors in 2025

Updated Category News Views 667

Global Financial Markets Prepare for 2025 Global financial markets are gearing up for an important year ahead. As we approach 2025, significant changes in currency markets and commodity prices are predicted to present both challenges and opportunities for investors, traders, and market analysts. This article delves into five major themes expected to shape the financial...

Continue Reading
Exploring Synovus Financial Inc's Earnings Potential and Metrics

Updated Category News Views 194

Understanding Synovus Financial Inc's Current Stock Performance In today's market, Synovus Financial Inc. (NYSE: SNV) is priced at $45.89, reflecting a 1.30% rise. However, the recent history shows a decline, with the stock falling by 7.83% over the last month and 6.52% over the past year. This fluctuation raises questions among shareholders about the stock's potential...

Continue Reading
Buffett's Strategic Exit from Key ETFs: Analyzing Implications

Updated Category News Views 387

Buffett's Recent Moves in the ETF Landscape Recently, Berkshire Hathaway made headlines as it divested from two key S&P 500 ETFs, including the Vanguard S&P 500 ETF, the largest of its kind globally. This bold decision has raised eyebrows in the investment community, leading many to ponder what insights this could offer into the mind of Warren Buffett, often revered as...

Continue Reading
Global Partnership Enhances Remote Employee Verification Solutions

Updated Category News Views 105

Sumsub and TELUS Digital: A Powerful Partnership In today's rapidly evolving digital landscape, securing the workforce has never been more critical. With companies expanding their reach globally, the need for streamlined processes in employee verification and onboarding has risen to the forefront. Sumsub, a renowned full-cycle verification platform, has joined forces with...

Continue Reading
Analyzing Palantir Technologies' Latest Developments and Trends

Updated Category News Views 162

Palantir Expands PFCS Forward Authorization Palantir Technologies is making significant strides with its PFCS Forward, which has recently broadened its Provisional Authorizations for Impact Level 5 and Impact Level 6 to encompass both on-premises and edge deployments. This strategic move facilitates a more versatile implementation of its technology across numerous...

Continue Reading